For long-term investors, Procter & Gamble presents a compelling opportunity due to its strong fundamentals and growth prospects. PG’s consistent financial performance, characterized by steady revenue growth and robust profit margins, underscores its resilience and ability to generate shareholder value. The company’s strong brand portfolio and market leadership in...
Expecting price to correct upwards between $13.73 and $16.49 in minor C followed by intermediate (C) in ((2)) to between the 61.8% or the 85.4% trend based fib extension. Invalid below 0.5525 cents.
GSK is trading around the multi year lows having bounced off of the long term support zone at 1300. I think this is a relative bargain at these levels with GSK being one of the Big Pharma Companies that is still trading way below the starting price for the year. Pfizer, Johnson & Johnson and Roche are all either positive or around net zero YTD. Novartis is...
$NEWT is one of the stocks we monitor in our income stock watchlist. I like how it's setting up for a buy here, normally it falls after going ex-dividend, since investors leg into it ahead of the dividend being paid, and exit after receiving it. This is a reliable pattern in this stock. Technicals show price met a downtrend target slightly ahead of time, and as...